Polarean Imaging (POLX) the medical-imaging technology company, told investors on Wednesday it received another order research unit order for its 9820 Xenon Polariser system.
Polarean makes a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market.
The order came from the Hospital for Sick Children in Toronto, “SickKids”, a major paediatric research and teaching hospital with an earlier model of Polarean’s polariser.
This new unit will expand SickKids' ongoing paediatric research programme using hyperpolarised gas imaging.
Their order was enabled by a grant from the Canada Foundation for Innovation.
Richard Hullihen, CEO of Polarean, said: "We are very happy to extend our long-standing relationship with SickKids Hospital in Toronto who work tirelessly on the paediatric applications of hyperpolarised xenon imaging for this important patient population."
Polarean’s focus on pulmonary imaging using hyperpolarized gas MRI technology is a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods.
According to the company the number of polarisers installed or on order to date is 24.
Polarean is backed by Amphion Innovations, who invest in high growth companies in the medical and technology sectors.
Follow News & Updates from Polarean here: